Contributors

L. A. Arvanitis, Senior Director, CNS Clinical Research, Zeneca Pharmaceuticals, Wilmington, Delaware, USA

William T. Carpenter, Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine, and Director, Maryland Psychiatric Research Center, Baltimore, USA

Daniel E. Casey, Professor of Psychiatry and Neurology, Oregon Health Sciences University, and Chief, Psychiatric Research and Pharmacology, Veterans Administration Medical Center, Portland, Oregon, USA

Lars Farde, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden

W. Wolfgang Fleischhacker, Professor of Psychiatry, Head, Department of Biological Psychiatry, Innsbruck University Hospital Innsbruck, Austria

J. M. Goldstein, Assistant Director, CNS Clinical Research, and Principal Pharmacologist, Zeneca Pharmaceuticals, Wilmington, Delaware, USA

Christer Halldin, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden

Steven R. Hirsch, Professor of Psychiatry, Charing Cross and Westminster Medical School, London

Jeffrey A. Lieberman, Professor of Psychiatry and Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Christopher G. G. Link, Drug Team Leader, Zeneca Pharmaceuticals, Mereside, Alderly Park, Macclesfield, UK

Ullrich Meise, Associate Professor of Psychiatry, Department of General Psychiatry, Innsbruck University Hospital, Innsbruck, Austria

Herbert Y. Meltzer, Professor of Psychiatry, Case Western Reserve University School of Medicine, and Vice Chairman of Research, University Hospitals, Cleveland, Ohio, USA

Yoshifumi Nakashima, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden

Anna-Lean Nordström, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden

Svante Nyberg, Consultant, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden

https://doi.org/10.1192/S0007125000298243 Published online by Cambridge University Press